• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Elizabeth Mitchell Discusses the Pace of Payment Reform and Transparency

Video

Payment reform in the US is progressing considerably, but more transparency is necessary in order to change payment for the better in the United States, said Elizabeth Mitchell, president and CEO of the Network for Regional Healthcare Improvement.

Payment reform in the US is progressing considerably, but more transparency is necessary in order to change payment for the better in the United States, said Elizabeth Mitchell, president and CEO of the Network for Regional Healthcare Improvement.

Transcript (slightly modified)

How do you see the pace of payment reform moving?

I think there is considerable momentum for change, at the regional level, at the national level, and across both the public and private sectors. I think the US Department of Health and Human Services (HHS) has been an incredible leader in driving payment reform, but I’m also seeing the commercial sector health plans, employers and providers, get increasingly ready for transformative change. So I see a lot of momentum and a lot of movement.

How closely intertwined is transparency with a value- and performance-based healthcare system?

Well, I think transparency is absolutely necessary but insufficient. I actually think Congress presumed that there was transparent information available when they passed MACRA [Medicare Access and CHIP Reauthorization Act] because you can’t pay for value if you don’t have any way to define it.

So without transparent performance information we’re going to have a very hard time not only changing payment, but evaluating the impact of that. I think there is going to be increasing demand from those moving towards value payment to really have some way to learn what’s happening, to set targets, to set priorities, and then to evaluate impact.

Related Videos
Michael David Chuong, MD, radiation oncologist, Miami Cancer Institute, Baptist Health South Florida
Yuman Fong, MD, cancer surgeon, City of Hope
Dr Marco del Riccio
Elena Elimova, MD, associate professor in the Department of Medicine at the University of Toronto and staff medical oncologist at Princess Margaret Hospital
Dr Eric Yang
Adam Brufsky, MD, PhD, University of Pittsburgh
Enrique Velazquez Villarreal, MD, PhD, MPH, MS, assistant professor in the department of integrative translational sciences at City of Hope
Dr Marco Del Riccio
Dr Steven Manobianco
© 2026 MJH Life Sciences
AJMC®
All rights reserved.